Optimi Health Corp. is a commercial-stage psychedelic drug manufacturer that produces MDMA capsules and natural psilocybin extract. The company operates a GMP-licensed manufacturing platform approved by Health Canada and supplies finished-dose products to authorized prescribers in Australia under the TGA Authorized Prescriber Scheme. Its business model focuses on supplying regulated treatment programs and research initiatives rather than conducting clinical trials as a drug developer. The company tracks supply status across various jurisdictions, including active commercial exports and special-access pathways, while evaluating infrastructure for potential expansion into additional markets.

Summarised from the company's own disclosures

Industry Drug Manufacturers - Specialty & Generic Homepage ir.optimi.net
Sector Healthcare IR page ir.optimi.net
Tags
psychedelic drugs, mdma, psilocybin, gmp manufacturing, regulated treatment programs, specialty pharmaceuticals, MDMA capsules, natural psilocybin extract
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 38
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Proposed OPTI-101 protocol amendment converts the single-arm, open-label Phase 2 trial into a randomized, double-blind Phase 2b in severe major depressive disorder, enhancing statistical power; dosing expected Q1 2027 with topline data expected in 2028

Health Canada-cleared Phase 3 trial of OPTI-201 MDMA-assisted therapy in 100 veterans and front-line workers with PTSD expected to begin in 2027; Company plans to file a U.S. IND for OPTI-201 in addition to the proposed Canadian trial.

VANCOUVER, British Columbia, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical drug developer and manufacturer of regulated psychedelic drug products, provides an update on its clinical programs, commercial supply, Ibogaine Initiative and a shares-for-debt settlement.

Highlights

OPTI-101: naturally derived psilocybin for major depressive disorder (MDD)

Phase 2b Trial: randomized, double-blind, active placebo-controlled trial in 200 adults with severe MDD; dosing expected to begin in Q1 2027; topline data expected in 2028.

U.S. FDA Pathway: preparing an IND for the FDA ahead of a planned U.S.

New wholly owned subsidiary, led by Adrian Jones, to expand the Company's network of clinics and pharmacies across Australia

New wholly owned subsidiary, led by Adrian Jones, to expand the Company's network of clinics and pharmacies across Australia

VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical developer and manufacturer of regulated psychedelic drug products, today announced the establishment of Optimi Australia Pty Ltd ("Optimi Australia"), a wholly owned subsidiary responsible for distribution and business development in Australia, and the appointment of Adrian Jones as Director of Australian Operations.

Optimi Australia will handle the Company's sales, distribution, and prescriber relationships across the country. It will sell Optimi's finished drug products, 5mg naturally derived psilocybin capsules and 40mg and 60mg MDMA capsules, to clinics and pharmacies under Australia's Authorised Prescriber Scheme. All products are manufactured at the Company's Health Canada-licensed GMP facility in Princeton, British Columbia.

Mr. Jones joins Optimi after more than 15 years at Bristol Myers Squibb, most recently as Associate Director, Head of Sales and Marketing for its Australian oncology and cardiovascular portfolios, where he led national commercial teams and served as launch lead for first-in-class therapies including Opdivo and Camzyos. His early career includes psychiatry roles with Eli Lilly and Hospira.

"Australia is our first commercial market and we believe demand from authorized prescribers there continues to grow," said Dane Stevens, Chief Executive Officer of Optimi. "Optimi Australia puts our team on the ground, and in Adrian we have a leader with extensive experience launching new therapies in this market."

"My immediate focus is to understand the needs of the clinician and to help them deliver therapy as efficiently and effectively as possible," said Adrian Jones, Director of Australian Operations.

Authorised prescribers, clinics, and pharmacies seeking product information or account setup can contact Adrian Jones at [email protected] or visit the Company's Australian website, www.optimi.com.au

Batch sufficient to supply the proposed Canadian Phase 3 trial, a clinical trial in Israel in partnership with MAPS and a commercial export to treat PTSD in Australia

Batch sufficient to supply the proposed Canadian Phase 3 trial, a clinical trial in Israel in partnership with MAPS and a commercial export to treat PTSD in Australia

Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers

VANCOUVER, British Columbia, Oct. 20, 2026 (GLOBE NEWSWIRE) --  Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of its latest production batch of its MDMA (3,4-methylenedioxymethamphetamine) finished drug product. The capsules were manufactured at Optimi’s GMP facility in Princeton, British Columbia, under its Health Canada Drug Establishment Licence, and are expected to supply three programs: the recently announced proposed Phase 3 clinical trial of MDMA-assisted therapy

in Canada (the “Proposed Phase 3 Trial”) for the treatment of post-traumatic stress disorder ("PTSD"), its next commercial export to Australia planned before the end of 2026, and a previously announced clinical trial in Israel in partnership with the Multidisciplinary Association for Psychedelic Studies ("MAPS").

The Proposed Phase 3 Trial is intended to enroll up to 100 participants across multiple sites in Canada, focusing on veterans and current or former frontline workers. Participants are expected to receive the Company's synthetic MDMA hydrochloride, supplied in two dosage formats, during two supervised sessions combining MDMA and psychotherapy spaced several weeks apart, with follow-up evaluations after the final session. The primary efficacy endpoint will be change in the Clinician-Administered PTSD Scale (CAPS-5), which is the standard clinician-rated instrument for assessing PTSD severity. The Proposed Phase 3 Trial is expected to begin in 2027.

Optimi has received Australian import permits for MDMA, with the next shipment planned before the end of 2026 to supply clinics and pharmacies across the country through Optimi Australia. In Australia, clinicians are authorized to prescribe MDMA capsules to patients with PTSD under the Therapeutic Goods Administration's Authorised Prescriber Scheme, with reimbursement from public and private payers including the Department of Veterans' Affairs, the National Disability Insurance Scheme, WorkCover, and Medibank. More than 750 clinicians have completed Mind Medicine Australia’s Certificate in Psychedelic-Assisted Therapies, and Optimi is not aware of any reported serious adverse events among patients since commercial supply began in 2024.

"Veterans in Australia can already access MDMA-assisted therapy through their own government. Veterans in Canada cannot,” said Dane Stevens, Optimi Chief Executive Officer and Co-Founder. "The Canadian Phase 3 trial is how we hope to close that gap, and the medicine for that trial is already made. We are proud to supply MDMA commercially to clinics in Australia, and we are keeping a keen eye on the United States and other jurisdictions as access expands.”

The safety and efficacy of MDMA-assisted therapy to treat PTSD is still under investigation in Canada, and none of Optimi’s MDMA drug products have received market authorization by Health Canada.

As previously announced on November 26, 2025, Optimi supplies the MDMA capsules for MAPS Israel’s Healing October 7th project, which includes a clinical trial for PTSD that has received formal approval from the Israeli Ministry of Health. Further details on this clinical trial can be found in Optimi’s November 26, 2025 press release.

Prompts

Optimi Health Corp. (ticker OPTH), listed in United States.

ETFs Holding Optimi Health Corp.

ETF Weight in ETF Shares Market value As of
PSIL 1.47% 266,914 $ 560.519K Nov 17, 2026